ARTICLE | Company News
Emergent BioSolutions, Abbott deal
January 2, 2012 8:00 AM UTC
Emergent said Abbott will terminate a 2009 deal to co-develop and commercialize Emergent's cancer product TRU-016. Abbott's decision is a result of a portfolio prioritization process, according to Emergent. Until the termination becomes effective on March 20, Abbott remains responsible for half of collaboration project costs and any milestone payments (see BioCentury, Aug. 31, 2009). ...